Breaking News, Collaborations & Alliances

Myrtelle and Forge Biologics Enter Manufacturing Partnership

To advance Myrtelle’s novel gene therapy for monogenic hearing loss for Phase 1/2 clinical trials.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), have formed a manufacturing partnership that will advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with autosomal recessive deafness 8 (DFNB8). Forge will provide research-grade and GMP-Pathway plasmi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters